Literature DB >> 15174978

Yersinia pestis (plague) vaccines.

Richard W Titball1, E Diane Williamson.   

Abstract

Live attenuated and killed whole cell vaccines against disease caused by Yersinia pestis have been available since the early part of the last century. Although these vaccines indicate the feasibility of protecting against disease, they have a number of shortcomings. The live attenuated vaccine is highly reactogenic and is not licensed for use in humans. The killed whole cell vaccine, also reactogenic, provides poor protection against pneumonic plague and immunisation requires multiple doses of the vaccine. Against this background, a range of candidate vaccines, including rationally attenuated mutants, subunit vaccines and naked DNA vaccines have been described. Of these, an injected subunit vaccine is likely to offer the best near-term solution to the provision of a vaccine that protects against both bubonic and pneumonic plague.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15174978     DOI: 10.1517/14712598.4.6.965

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  69 in total

1.  Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.

Authors:  Juliette K Tinker; Chadwick T Davis; Britni M Arlian
Journal:  Protein Expr Purif       Date:  2010-05-11       Impact factor: 1.650

2.  Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis.

Authors:  Clarissa Cowan; Alexander V Philipovskiy; Christine R Wulff-Strobel; Zhan Ye; Susan C Straley
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.

Authors:  Alexander V Philipovskiy; Stephen T Smiley
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

4.  Administration of antibody to the lung protects mice against pneumonic plague.

Authors:  Jim Hill; Jim E Eyles; Stephen J Elvin; Gareth D Healey; Roman A Lukaszewski; Richard W Titball
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

5.  Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

Authors:  Jeremy L Goodin; David F Nellis; Bradford S Powell; Vinay V Vyas; Jeffrey T Enama; Lena C Wang; Patrick K Clark; Steven L Giardina; Jeffery J Adamovicz; Dennis F Michiel
Journal:  Protein Expr Purif       Date:  2006-12-31       Impact factor: 1.650

6.  Evaluation of combinatorial vaccines against anthrax and plague in a murine model.

Authors:  Amanda B DuBois; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

7.  Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens.

Authors:  V A Feodorova; L N Pan'kina; E P Savostina; O S Kuznetsov; N P Konnov; L V Sayapina; S V Dentovskaya; R Z Shaikhutdinova; S A Ageev; B Lindner; A N Kondakova; O V Bystrova; N A Kocharova; S N Senchenkova; O Holst; G B Pier; Y A Knirel; A P Anisimov; V L Motin
Journal:  Vaccine       Date:  2009-02-13       Impact factor: 3.641

8.  Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.

Authors:  Wei Sun; Kenneth L Roland; Xiaoying Kuang; Christine G Branger; Roy Curtiss
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

Review 9.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

10.  Yersinia pestis caf1 variants and the limits of plague vaccine protection.

Authors:  Lauriane E Quenee; Claire A Cornelius; Nancy A Ciletti; Derek Elli; Olaf Schneewind
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.